A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis (WAYPOINT)
Chronic rhinosinusitis with nasal polyps
18 Years - n/a
Endpoint Classification: -
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Verified 01 Aug 2023 by AstraZeneca
No locations available
Tezepelumab subcutaneous injection, in an accessorized pre-filled syringe.
Biological/Vaccine: Experimental: Tezepelumab
Tezepelumab subcutaneous injection
Other Name: Tezepelumab
|Placebo Comparator: Placebo|
Placebo subcutaneous injection, in an accessorized pre-filled syringe.
Placebo subcutaneous injection
Other Name: Placebo